These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Ritonavir and indinavir one year later. TreatmentUpdate; 2001; 12(12):6-7. PubMed ID: 11570094 [No Abstract] [Full Text] [Related]
8. Indinavir urinary stones as origin of upper urinary tract obstruction. John H; Müller NJ; Opravil M; Hauri D Urol Int; 1997; 59(4):257-9. PubMed ID: 9444746 [TBL] [Abstract][Full Text] [Related]
9. Urinary stones in HIV-1-positive patients treated with indinavir. Daudon M; Estépa L; Viard JP; Joly D; Jungers P Lancet; 1997 May; 349(9061):1294-5. PubMed ID: 9142068 [No Abstract] [Full Text] [Related]
10. Urolithiasis and the protease inhibitor indinavir. Hermieu J; Prévot M; Ravery V; Sauty L; Moulinier F; Delmas V; Bouvet E; Boccon-Gibod L Eur Urol; 1999; 35(3):239-41. PubMed ID: 10072627 [TBL] [Abstract][Full Text] [Related]
11. [Ureteral lithiasis caused by Indinavir]. Valero G; Leyton R; Valenzuela A Rev Med Chil; 2002 May; 130(5):557-9. PubMed ID: 12143277 [TBL] [Abstract][Full Text] [Related]
12. Platelet dysfunction as the cause of spontaneous bleeding in two haemophilic patients taking HIV protease inhibitors. Pollmann H; Richter H; Jürgens H Thromb Haemost; 1998 Jun; 79(6):1213-4. PubMed ID: 9657450 [No Abstract] [Full Text] [Related]
15. [Treatment of HIV infections and AIDS with protease inhibitor and two nucleoside analogs]. Jensen-Fangel S; Larsen L; Thomsen HF; Nielsen LP; Black FT; Obel N Ugeskr Laeger; 1999 Mar; 161(12):1751-4. PubMed ID: 10210974 [TBL] [Abstract][Full Text] [Related]
16. Rapid development of indinavir-induced asymptomatic crystalluria in a human immunodeficiency virus-negative patient. Antony SJ Clin Infect Dis; 1998 Oct; 27(4):911-2. PubMed ID: 9798063 [No Abstract] [Full Text] [Related]
17. Indinavir and thrombocytopenia. Durand JM AIDS; 1999 Jan; 13(1):148-9. PubMed ID: 10207566 [No Abstract] [Full Text] [Related]
19. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy. Badía X; Podzamczer D; Moral I; Roset M; Arnaiz JA; Loncà M; Casiró A; Rosón B; Gatell JM; Antivir Ther; 2004 Dec; 9(6):979-85. PubMed ID: 15651756 [TBL] [Abstract][Full Text] [Related]
20. Ureteral obstruction secondary to indinavir in the pediatric HIV population. Noble CB; Klein LT; Staiman VR; Neu N; Hensle TW; Berdon WE Pediatr Radiol; 1998 Aug; 28(8):627-9. PubMed ID: 9716639 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]